Strategic partnerships Daiichi Sankyo US is actively engaging in external research collaborations with biotech startups and academia (Interna Therapeutics, 4D Path, DoriNano, General Proximity) to advance delivery platforms, predictive biomarkers, and ADC programs, presenting near-term opportunities to align co-development or sponsored research agreements with their Boston Research Institute and US teams.

Clinical pipeline focus The company emphasizes cancer and cardiovascular domains with high unmet medical need and features a robust portfolio around antibody drug conjugates and targeted therapies, suggesting sales opportunities in niche oncology collaborations, companion diagnostics, and biomarker-enabled trial support services.

Expansion potential Recent headcount growth in oncology sales and ongoing partnerships indicate a push to broaden market access and field presence, signaling opportunities for sales enablement, medical affairs alignment, and regional support resources to accelerate product adoption.

Digital and data readiness Adoption of technologies like Google Analytics 4, AWS, SAP Concur, and data-oriented collaboration tools points to a data-driven operating model, opening doors for services in digital health analytics, cloud-based trial data management, and integrated spend optimization for partnerships.

Strategic growth signals Active engagement in high-profile conferences (IASLC World Conference), significant collaboration announcements, and international leadership (Tokyo and US presence) indicate a readiness to explore strategic partnerships, co-commercialization, and contract research opportunities across markets.